PDX: Moving Beyond Drug Screening to Versatile Models for Research Discovery-Reference-Cited by-同舟云学术

PDX: Moving Beyond Drug Screening to Versatile Models for Research Discovery

Published:2020-09-12 Issue:11 Volume:4 Page:
ISSN:2472-1972
Container-title:Journal of the Endocrine Society
language:en
Short-container-title:

Author:

Risbridger Gail P¹²³^ORCID,Lawrence Mitchell G¹²³^ORCID,Taylor Renea A²³⁴^ORCID

Affiliation:

1. Department of Anatomy and Developmental Biology, Biomedicine Discovery Institute Cancer Program, Monash University, Melbourne, Victoria, Australia

2. Prostate Cancer Research Program, Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

3. Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia

4. Department of Physiology, Biomedicine Discovery Institute Cancer Program, Monash University, Melbourne, Victoria, Australia

Abstract

Abstract Patient-derived xenografts (PDXs) are tools of the trade for many researchers from all disciplines and medical specialties. Most endocrinologists, and especially those working in oncology, commonly use PDXs for preclinical drug testing and development, and over the last decade large collections of PDXs have emerged across all tumor streams. In this review, we examine how the field has evolved to include PDXs as versatile resources for research discoveries, providing evidence for guidelines and changes in clinical practice.

Funder

National Health and Medical Research Council

Prostate Cancer Research Program

U.S. Department of Health and Human Services

Victorian Cancer Agency

CASS Foundation

EJ Whitten Foundation

Peter and Lyndy White Foundation

TissuPath Pathology

Publisher

The Endocrine Society

Subject